Synkrino Development Company (SDC) partners with biotech to finance and develop innovative high impact therapeutics programs.
We serve the entire pharma ecosystem of patients, prescribers, payers, biotechs, and pharma companies by financing, accelerating, and pushing forward drug candidates with the potential to significantly improve the standard of care – offering a new range of therapeutic options that balance price and treatment outcome.
Our process creates portfolios of orthogonal assets (biological target, disease indication, modality) with the aim of de-risking biotech investments for institutional investors. We partner with biotech on an asset basis – not a company basis – creating a stream of uncorrelated cash flows with a superior return-on-investment profile.
Company Details
- Employees
- 6
- Address
- Boston, Cambridge, Massachusetts, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://synkrino.dev
- Keywords
- IT Consulting.
- HQ
- Boston, Cambridge, Massachusetts
Synkrino Development Company, Llc Questions
Synkrino Development Company, Llc's website is https://synkrino.dev
Synkrino Development Company, Llc's LinkedIn profile is https://www.linkedin.com/company/synkrino-development-company
Synkrino Development Company, Llc has
6 employees.
View email and phone details for 6
employees at Synkrino Development Company, Llc.
Synkrino Development Company, Llc's industry is
Biotechnology Research
Synkrino Development Company, Llc's top competitors are
Simply Good,
Khora Therapeutics,
Pi Health Sciences Ltd,
Nooks,
Vir2us, Inc.,
Barbour Bio,
Aragen Life Sciences,
Posterus Partners,
Salus Optima,
Syngene International Limited.
Synkrino Development Company, Llc's categories are Biotechnology Research
